



- (51) **International Patent Classification:**
A61K 31/517 (2006.01) *C07D 239/70* (2006.01)
- (21) **International Application Number:**
PCT/US2012/031720
- (22) **International Filing Date:**
30 March 2012 (30.03.2012)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/470,803 1 April 2011 (01.04.2011) US
61/470,624 1 April 2011 (01.04.2011) US
- (71) **Applicant (for all designated States except US):** GEN-ENTECH, INC. [US/US]; 1 Dna, South San Francisco, California 94080-4990 (US).
- (72) **Inventors; and**
- (71) **Applicants :** LIN, Kui [US/US]; 1 DNA Way, South San Francisco, California 94080-4990 (US). NANNINI, Michelle [US/US]; 1 DNA Way, South San Francisco, California 94080-4990 (US). PUNNOOSE, Elizabeth [US/US]; 1 DNA Way, South San Francisco, California 94080-4990 (US). SAMPATH, Deepak [US/US]; 1 DNA Way, South San Francisco, California 94080-4990 (US). WALLIN, Jeffrey [US/US]; 1 DNA Way, South San Francisco, California 94080-4990 (US). PATEL, Premel [US/US]; 1 DNA Way, South San Francisco, California 94080-4990 (US).
- (74) **Agents:** VIKSNINS, Ann, S., et al.; Viksnins Harris & Padys PLLP, P.O. Box 111098, St. Paul, Minnesota 55111-1098 (US).
- (81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declarations under Rule 4.17:**
— of inventorship (Rule 4.17(iv))
- Published:**
— with international search report (Art. 21(3))

(54) **Title:** COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE





FIG. 1



(I)

(57) **Abstract:** The invention provides combinations comprising a) a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein R¹, R², R⁵, R¹⁰, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.